Antifungal Antagonism Screening

抗真菌拮抗剂筛选

• 批准号: 10919697
• 负责人: Alexey Zakharov
• 金额: $ 24.08万
• 依托单位: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10919697
• 关键词: Amphotericin B; Antifungal Agents; Antifungal Therapy; Aspergillus fumigatus; Automobile Driving; Azoles; Basic Science; Biological Assay; Candida albicans; Cryptococcus neoformans; Fungal Drug Resistance; Health; Human; Human Genome; Mycoses; National Center for Advancing Translational Sciences; Patients; Pharmaceutical Preparations; Predisposition; Rare Diseases; Reporting; Research; Translations; Work; antagonist; clinical efficacy; drug candidate; high throughput screening; improved; mortality; pathogenic fungus; pharmacologic; programs; resistance mechanism; screening; tool

The NCATS Early Translation Branch (ETB) hosts a broad and comprehensive program for the discovery of drug candidates directed towards rare diseases and pharmacological tools to probe the function of the human genome. ETB conducts research to understand the underlying principles driving the translation of basic research discoveries into tangible improvements in human health. During the reporting period, the collaborative team worked to develop a high-throughput screening assay to identify compounds that reduce the susceptibility of four major human fungal pathogens (C. albicans, C. glabrata, C. neoformans and A. fumigatus) to the most commonly used classes of antifungal drugs (azoles, amphotericin B and echinocandins). This will identify a list of medications that may undermine the clinical efficacy of currently used antifungal drugs.

NCATS早期翻译分支（ETB）拥有一个广泛而全面的计划，用于发现针对罕见疾病的候选药物和探索人类基因组功能的药理学工具。ETB开展研究，以了解推动基础研究发现转化为人类健康切实改善的基本原则。 在本报告所述期间，该合作小组致力于开发一种高通量筛选试验，以鉴定降低四种主要人类真菌病原体（C。白色念珠菌、C.光叶C. Neoformans和A.烟曲霉）到最常用的抗真菌药物类别（唑类、阿替霉素B和棘白菌素）。这将确定可能破坏当前使用的抗真菌药物的临床疗效的药物列表。